Access to the current activities is restricted to CATAG members and can only be accessed by way of Member Login.
In the future, the outcomes of CATAG activities will be collated and made available to members via Member Login. The outcomes of earlier discussions are not available.
Current questions and discussion topics can be accessed via Member Login.
Information sharing and discussion
Between 2005 and 2013, the following topics were considered by CATAG members:
Botulinum toxin A: access for non-PBS indications
Conflict of interest documents
Current key performance indicator data
Drotrecogin (Xigris) guidelines and aggregated audit results
Generic medicines: reports of issues
Heparins in VTE prophylaxis
High cost drug submission documents
High risk medicines: Sharing incident data
Individual patient use/individual patient approval forms
Key performance indicators
Medication Safety Self Assessment/QUM indicators
Naltrexone in Multiple Sclerosis
Off-label use of drugs: list medicines and indications for which off-label use is considered standard practice
Pharmaceutical company liaison
Product familiarisation programs
Self-funding high-cost drugs
Using patients own drugs
Off-label use of rituximab: A prospective online survey tool collected data for a six month period April 2012 to October 2012 from Australian public hospitals.
Publication: O’Connor, K. and Liddle, C.(2013) Prospective data collection of off-label use of rituximab in Australian public hospitals.
Internal Medicine Journal, 43: 863–870. doi: 10.1111/imj.12206
Development of Guiding Principles for the roles and responsibilities of Drug and Therapeutics Committees in Australian public hospitals, 2013
Development of Guiding Principles for the quality use of off-label medicines, 2013